These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 26545798

  • 21. Pharmacophore-based virtual screening, molecular docking and molecular dynamics simulations study for the identification of LIM kinase-1 inhibitors.
    Singh R, Pokle AV, Ghosh P, Ganeshpurkar A, Swetha R, Singh SK, Kumar A.
    J Biomol Struct Dyn; 2023; 41(13):6089-6103. PubMed ID: 35862656
    [Abstract] [Full Text] [Related]

  • 22. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
    Sleebs BE, Nikolakopoulos G, Street IP, Falk H, Baell JB.
    Bioorg Med Chem Lett; 2011 Oct 01; 21(19):5992-4. PubMed ID: 21852129
    [Abstract] [Full Text] [Related]

  • 23. Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
    Collins R, Lee H, Jones DH, Elkins JM, Gillespie JA, Thomas C, Baldwin AG, Jones K, Waters L, Paine M, Atack JR, Ward SE, Grubisha O, Foley DW.
    J Med Chem; 2022 Oct 27; 65(20):13705-13713. PubMed ID: 36205722
    [Abstract] [Full Text] [Related]

  • 24. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
    Yin Y, Lin L, Ruiz C, Khan S, Cameron MD, Grant W, Pocas J, Eid N, Park H, Schröter T, Lograsso PV, Feng Y.
    J Med Chem; 2013 May 09; 56(9):3568-81. PubMed ID: 23570561
    [Abstract] [Full Text] [Related]

  • 25. Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.
    Pan J, Yin Y, Zhao L, Feng Y.
    Bioorg Med Chem; 2019 Apr 01; 27(7):1382-1390. PubMed ID: 30819619
    [Abstract] [Full Text] [Related]

  • 26. Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid.
    Henderson BW, Greathouse KM, Ramdas R, Walker CK, Rao TC, Bach SV, Curtis KA, Day JJ, Mattheyses AL, Herskowitz JH.
    Sci Signal; 2019 Jun 25; 12(587):. PubMed ID: 31239325
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Development and design of novel cardiovascular therapeutics based on Rho kinase inhibition-In silico approach.
    Ćirić Zdravković S, Pavlović M, Apostlović S, Koraćević G, Šalinger Martinović S, Stanojević D, Sokolović D, Veselinović AM.
    Comput Biol Chem; 2019 Apr 25; 79():55-62. PubMed ID: 30716601
    [Abstract] [Full Text] [Related]

  • 29. Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.
    Manetti F.
    Eur J Med Chem; 2018 Jul 15; 155():445-458. PubMed ID: 29908439
    [Abstract] [Full Text] [Related]

  • 30. Discovery of Rho-kinase inhibitors by docking-based virtual screening.
    Shen M, Yu H, Li Y, Li P, Pan P, Zhou S, Zhang L, Li S, Lee SM, Hou T.
    Mol Biosyst; 2013 Jun 15; 9(6):1511-21. PubMed ID: 23549429
    [Abstract] [Full Text] [Related]

  • 31. 3D-QSAR studies on indole and 7-azoindole derivatives as ROCK-2 inhibitors: An integrative computational approach.
    Nagarajan SK, Babu S, Sohn H, Devaraju P, Madhavan T.
    Comput Biol Chem; 2017 Dec 15; 71():104-116. PubMed ID: 29153889
    [Abstract] [Full Text] [Related]

  • 32. The Nature of Diamino Linker and Halogen Bonding Define Selectivity of Pyrrolopyrimidine-Based LIMK1 Inhibitors.
    Ariawan D, Au C, Paric E, Fath T, Ke YD, Kassiou M, van Eersel J, Ittner LM.
    Front Chem; 2021 Dec 15; 9():781213. PubMed ID: 34966720
    [Abstract] [Full Text] [Related]

  • 33. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators.
    Manetti F.
    Med Res Rev; 2012 Sep 15; 32(5):968-98. PubMed ID: 22886629
    [Abstract] [Full Text] [Related]

  • 34. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S, Zeng G, Fang D, Wang J, Wu W, Xie W, Tan S, Zheng K.
    Mol Biosyst; 2015 Feb 15; 11(2):394-406. PubMed ID: 25406390
    [Abstract] [Full Text] [Related]

  • 35. Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study.
    Tarazi H, El-Gamal MI, Oh CH.
    Bioorg Med Chem; 2019 Feb 15; 27(4):655-663. PubMed ID: 30660499
    [Abstract] [Full Text] [Related]

  • 36. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.
    Tang J, Lackey KE, Dickerson SH.
    Bioorg Med Chem Lett; 2013 Jan 01; 23(1):66-70. PubMed ID: 23218715
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
    Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L.
    Bioorg Med Chem; 2015 Nov 15; 23(22):7340-7. PubMed ID: 26526740
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Jak2 inhibitor--a jackpot for pharmaceutical industries: a comprehensive computational method in the discovery of new potent Jak2 inhibitors.
    Singh KhD, Naveena Q, Karthikeyan M.
    Mol Biosyst; 2014 Aug 15; 10(8):2146-59. PubMed ID: 24874539
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.